Brostallicin Clinical Trial for Myxoid Liposarcoma (SMI-BRS-202)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2010 by Systems Medicine LLC.
Recruitment status was Active, not recruiting
Information provided by:
Systems Medicine LLC
First received: March 3, 2008
Last updated: February 24, 2010
Last verified: February 2010
This is a Phase II, multicenter, open-label clinical trial designed to determine the efficacy and safety of Brostallicin when administered once every 3 weeks in patients with myxoid liposarcoma with (12;16) translocation. The primary objective of this study is to determine the response rate following Brostallicin administration.
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase II, Multicenter Study to Explore the Efficacy and Safety of Brostallicin in Patients With Myxoid Liposarcoma With (12:16) Translocation
Primary Outcome Measures:
- To determine the overall response rate and response rate, as measured by RECIST criteria of myxoid liposarcoma with (12;16) translocation, to Brostallicin. [ Time Frame: Tumor measurements after every 2 cycles and there is no limit to the number of cycles. ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To describe the safety profile of Brostallicin when administered every 3 weeks in this patient population. [ Time Frame: Tumor measurements after every 2 cycles and there is no limit to the number of cycles. ] [ Designated as safety issue: Yes ]
- Duration of response [ Time Frame: Tumor measurements after every 2 cycles and there is no limit to the number of cycles. ] [ Designated as safety issue: No ]
- To determine progression free survival. [ Time Frame: Tumor measurements after every 2 cycles and there is no limit to the number of cycles. ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Primary Completion Date:
||October 2008 (Final data collection date for primary outcome measure)
Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patient has provided informed consent.
- Histologically confirmed myxoid liposarcoma.
- Patients with metastatic and/or unresectable myxoid liposarcoma that is progressive and standard curative measures do not exist or are no longer effective.
- Patient has measurable tumor on CT, spiral CT, or MRI scan that meet RECIST criteria.
- Age ≥18 years
- Karnofsky performance status (KPS) ≥ 70% (see Appendix III).
- Life expectancy of at least 3 months.
Acceptable liver function:
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST (SGOT), ALT (SGPT) and alkaline phosphatase ≤ 2.5 times ULN (if liver metastases are present, then ≤ 5 × ULN is allowed).
- Acceptable renal function: For all patients serum creatinine within normal limits, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m(2) for patients with creatinine levels above institutional normal.
Acceptable hematologic status:
- Absolute neutrophil count (ANC) ≥ 1500 cells/mm(3) (1.5 ×10(9)/L)
- Platelet count ≥ 100,000 platelet/mm(3) (100 ×10(9)/L)
- Hemoglobin ≥ 9 g/dL.
Patient received any of the following within the specified time period prior to initiation of treatment in this study:
- Chemotherapy, major surgery, significant traumatic injury, or irradiation, whether conventional or investigational within 28 days
- Mitomycin-C or nitrosurea within 42 days.
- ET-743 at any time (Stage 1 only).
Patients heavily pretreated with chemotherapy and radiation, defined as follows:
- ≥ 12 cycles of an alkylating agent-containing regimen, or
- > 2 cycles carboplatin, or
- > 2 cycles mitomycin C, or
- irradiation to 25% of bone marrow-containing areas, or
- high-dose chemotherapy requiring hematopoietic stem-cell reinfusion.
- Known hypersensitivity to any study drug component.
- Uncontrolled brain metastases in the judgement of the Investigator.
Abnormal cardiac or cardiovascular function, or serious cardiac illness or medical condition in the previous 6 months including, but not confined to:
- New York Heart Association (NYHA) grade 2 or higher congestive heart failure (CHF) or who has had angioplasty or placement of coronary stents within the previous 6 months
- Myocardial infarction within the past 6 months
- High-risk uncontrolled arrhythmias
- Angina pectoris that requires antianginal medication
- Has clinically significant valvular heart disease
- Evidence of transmural infarction on ECG
- Poorly controlled hypertension (e.g., blood pressure: systolic >180 mm Hg or diastolic >100 mm Hg).
- Pregnant or lactating females. All patients (males and females) who are fertile must agree to use an effective barrier method of birth control (i.e., latex condom, diaphragm, cervical cap, etc) to avoid pregnancy.
- Not recovered from acute toxicity of all previous therapy prior to enrollment.
- History of prior malignancies within 3 years, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast.
- Any evidence of serious and/or unstable pre-existing medical, psychiatric, or other condition (including laboratory abnormalities) that could interfere with patient safety or obtaining informed consent.
- Any active uncontrolled infection including AIDS, hepatitis B or C.
- Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow up schedule.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00633165
|Sarcoma Oncology Center
|Santa Monica, California, United States, 90403 |
Systems Medicine LLC
||Jack Singer, M.D.
No publications provided
||Mary Jo Schreifels/Clinical Project Manager, Cell Therapeutics, Inc. (Systems Medicine, L.L.C. is a wholly owned subsidiary of CTI)
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 3, 2008
||February 24, 2010
||United States: Food and Drug Administration
Keywords provided by Systems Medicine LLC:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 28, 2014
Neoplasms, Adipose Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type